Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA

Stock Track

04/15

Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.

The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.

This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1184551801"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184551801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184551801?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184551801","market":"hk","top_or_hot":-1,"title":"Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA","media":"Stock Track","content":"<p>Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.</p>\n<p>The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.</p>\n<p>This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-15 08:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.</p>\n<p>The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.</p>\n<p>This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1184551801","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184551801","pubTimestamp":1776211595,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Clarity Pharmaceuticals盘中大涨5.15%CU-64 SAR-BiPSMA商业制造交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":1},"content_text":"Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.\nThe company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.\nThis manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}